Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

1.3K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.3K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

845
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
845
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

4.3K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
4.3K
Metabolic States of the Body: The Postabsorptive State01:18

Metabolic States of the Body: The Postabsorptive State

1.6K
The postabsorptive state usually starts about four hours after a meal and lasts until the next meal is eaten. During this time, the digestive system stops absorbing nutrients, and the body uses stored energy reserves to maintain stable blood glucose levels.
Initially, glycogen stored in the liver is broken down to release glucose into the bloodstream, while glycogen in the muscles is broken down to supply glucose for energy directly within the muscle cells. As glycogen stores diminish,...
1.6K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

929
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
929
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

5.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nutritional Challenges in Post-Massive Weight Loss Body Contouring: Guidance for Plastic Surgeons on GLP-1 Agonists and Sleeve Gastrectomy.

Plastic and reconstructive surgery·2025
Same author

Characterizing obesity: A qualitative study.

Obesity pillars·2025
Same author

Weight regain after total meal replacement very low-calorie diet program with and with-out anti-obesity medications.

Obesity science & practice·2024
Same author

Evaluation of Out-of-Pocket Costs and Treatment Intensification With an SGLT2 Inhibitor or GLP-1 RA in Patients With Type 2 Diabetes and Cardiovascular Disease.

JAMA network open·2023
Same author

Real-world weight-loss effectiveness of glucagon-like peptide-1 agonists among patients with type 2 diabetes: A retrospective cohort study.

Obesity (Silver Spring, Md.)·2023
Same author

Association of formulary restrictions and initiation of an SGLT2i or GLP1-RA among Medicare beneficiaries with type 2 diabetes.

Diabetes research and clinical practice·2022
Same journal

Continuous Glucose Monitoring in Type 2 Diabetes: Clinical Outcomes, Disparities in Access, and Cost-effectiveness.

Current diabetes reports·2026
Same journal

Beyond Inflammation - A Multidisciplinary Approach to Managing Obesity and Cardiometabolic Risk in Inflammatory Bowel Disease.

Current diabetes reports·2026
Same journal

Climate Change and Diabetes Outcomes: Evidence from Climate-Vulnerable Regions.

Current diabetes reports·2026
Same journal

Efficacy and safety of once-weekly basal insulin analogs versus daily basal insulin analogs in adults with type 2 diabetes: a systematic review and meta-analysis.

Current diabetes reports·2026
Same journal

Use of Glucagon-Like Peptide-1 Receptor Agonists in Women with Type 2 Diabetes Before Pregnancy: Addressing the Dilemma in A Real-World Setting.

Current diabetes reports·2026
Same journal

Can Behavioral Interventions Promote Health Equity in Pediatric Type 1 Diabetes? A Narrative Review of Promising Treatments.

Current diabetes reports·2026
See all related articles

Related Experiment Video

Updated: Mar 25, 2026

Roux-en-Y Gastric Bypass Operation in Rats
07:37

Roux-en-Y Gastric Bypass Operation in Rats

Published on: June 11, 2012

24.5K

Post-Gastric Bypass Hypoglycemia.

Chevon M Rariy1,2, David Rometo3,4, Mary Korytkowski5,6

  • 1Division of Endocrinology, Diabetes, and Metabolism, University of Pittsburgh Medical Center (UPMC), 200 Lothrop Avenue, Pittsburgh, PA, 15225, USA. chevon.rariy@gmail.com.

Current Diabetes Reports
|February 13, 2016
PubMed
Summary
This summary is machine-generated.

Post-Roux-en-Y gastric bypass surgery hypoglycemia (PGBH) is a serious complication. This review details PGBH

Keywords:
Bariatric surgeryGastric bypassGlucagon-like peptide-1HypoglycemiaIncretinsNesidioblastosisObesity

More Related Videos

One-anastomosis Gastric Bypass OAGB in Rats
08:16

One-anastomosis Gastric Bypass OAGB in Rats

Published on: November 10, 2018

11.6K
A Protocol for Roux-en-Y Gastric Bypass in Rats using Linear Staplers
11:58

A Protocol for Roux-en-Y Gastric Bypass in Rats using Linear Staplers

Published on: August 21, 2021

6.1K

Related Experiment Videos

Last Updated: Mar 25, 2026

Roux-en-Y Gastric Bypass Operation in Rats
07:37

Roux-en-Y Gastric Bypass Operation in Rats

Published on: June 11, 2012

24.5K
One-anastomosis Gastric Bypass OAGB in Rats
08:16

One-anastomosis Gastric Bypass OAGB in Rats

Published on: November 10, 2018

11.6K
A Protocol for Roux-en-Y Gastric Bypass in Rats using Linear Staplers
11:58

A Protocol for Roux-en-Y Gastric Bypass in Rats using Linear Staplers

Published on: August 21, 2021

6.1K

Area of Science:

  • Endocrinology
  • Gastroenterology
  • Public Health

Background:

  • Obesity is a global health crisis linked to severe comorbidities like heart disease, diabetes, and cancer.
  • Bariatric surgery, particularly Roux-en-Y gastric bypass (RYGB), offers significant benefits for obesity and related conditions.
  • Increasing bariatric surgery rates necessitate awareness of potential complications.

Purpose of the Study:

  • To review the definition, history, and diagnosis of post-RYGB surgery hypoglycemia (PGBH).
  • To outline current treatment options and provide an assessment and algorithm for managing PGBH.
  • To enhance physician understanding of this challenging complication.

Main Methods:

  • Literature review of existing studies on PGBH.
  • Analysis of diagnostic criteria and historical perspectives.
  • Development of a treatment algorithm based on current evidence and clinical experience.

Main Results:

  • PGBH is a poorly understood but potentially life-threatening complication following RYGB.
  • The review synthesizes available information on PGBH's presentation and diagnosis.
  • Current treatment strategies and a proposed management algorithm are presented.

Conclusions:

  • Physicians must be vigilant for PGBH in patients post-RYGB.
  • A structured approach to diagnosis and management is crucial for patient outcomes.
  • Further research is needed to fully elucidate the pathophysiology and optimize PGBH treatment.